OncoImmunology · 2020 · 82 citations · 28 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyBiomarker-guided ImmunotherapyCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmune CheckpointsImmuno-oncology BiomarkersCheckpoint Inhibitor Response PredictionImmune Checkpoint BiomarkersImmune Checkpoint Inhibitor BiomarkersImmune Checkpoint Inhibitor ResponseImmune Checkpoint Inhibitor TherapyImmune Checkpoint ResponseMetastatic Renal Cell Carcinoma TherapyProgrammed Death-ligand 1 Biomarker
= .002)]. High sPD-1 and sBTN3A1 levels were also associated with best overall response by RECIST and objective response of >20%. The results were confirmed in a validation cohort of 20 mccRCC patients. The analysis of plasma dynamic changes after nivolumab showed a statistically significant decrease of sPD-1 after 2 cycles (Day 28) in the long-responder patients. Our study revealed that the plasma levels of sPD-1, sPD-L1, and sBTN3A1 can predict response to nivolumab, discriminating responders from non-responders already at therapy baseline, with the advantages of non-invasive sample collection and real-time monitoring that allow to evaluate the dynamic changes during cancer evolution and treatment.
28
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer, Bernard Escudier, Saby George et al. · New England Journal of Medicine · 2015 · 5.9K citations · Full text
Medicine, Oncology, Pharmacotherapy +17
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini, Elizabeth R. Plimack, V.P. Stus et al. · New England Journal of Medicine · 2019 · 3.4K citations · Full text
Medicine, Oncology, Pharmacology +9
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
Robert J. Motzer, Brian I. Rini, David F. McDermott et al. · Journal of Clinical Oncology · 2014 · 1.1K citations · Full text
Medicine, Immunology, Oncology +17
Robert J. Motzer, Brian I. Rini, David F. McDermott et al. · The Lancet Oncology · 2019 · 780 citations · Full text
Medicine, Oncology, Pharmacology +12